Navigation Links
Women With Atypia Nearly Eight Times More Likely to Develop Breast Cancer

Washington, June 30 (ANI): A new study has found that women with at least three sites of cellular atypia in breast tissue are nearly eight times more likely than average women to develop breast cancer.

Several earlier studies have shown that atypical hyperplasia (also called atypia) in breast tissue is a major risk factor for breast cancer. Women who have a breast biopsy and are diagnosed with atypia are considered at high risk.

Many are adviced to consider defensive medications such as tamoxifen or other risk-reducing approaches. However, questions remained from previous research on whether a positive family history further increases risk in women with atypia and for how long the increased risk in women with atypia lasts.

The most commonly used tool for risk prediction in women with atypia is the Gail model, which may predict inaccurately because our study shows that family history does not change risk significantly in women with atypia.

Our findings indicate that women with atypia have a higher absolute risk for breast cancer than previously estimated. This risk is 25 percent over 25 years and is much higher in women with multiple areas of atypia and calcification, says Amy Degnim, M.D., a Mayo Clinic surgeon and study author.

The Gail model predicts risk by using age at commencement of menses, age at birth of first child, number of previous breast biopsies, existence of atypia, and number of close relatives with breast cancer.

While the Mayo Clinic study found that family history did not further augment risk, age at diagnosis of atypia did have an effect on risk, with younger women (under age 45) more than twice as likely to develop breast cancer compared to women diagnosed with atypia after 55.

The number of areas of atypical hyperplasia was noteworthy as well. With one area of atypia, breast cancer risk was 2.3-fold compar
'"/>




Page: 1 2

Related medicine news :

1. Women suffer from sexual dysfunction too
2. Women find difficulty in calling it Quits
3. Women recognise faces better
4. Women more susceptible to brain damage from ecstasy
5. Good News For Women With Gestational Diabetes
6. Unsatisfactory Grade On Womens Health Issues
7. Risk for Pregnant Women
8. Womens strong sense of smell
9. Women need to exercise more to prevent obesity
10. Women benefit from consuming fish
11. Women are at risk with raised cholesterol
Post Your Comments:
(Date:10/6/2008)...pecial supplement of the Oct. 15,journal Cancer fo...iddle-income countries to implement breast cancer ...se among women worldwide., "Guidelines for Intern...ntation" developed by the Breast Health Global Ini...e allocation -- based on countries,overall econom...
(Date:10/6/2008)...ently posted detailed information on its Cimzia in... side effects caused by the drug and its family kn...side effects are the development of fatal infectio...hild patients. , Denver, ...r one resource for everything and anything legal o...
(Date:10/6/2008)...ased civil litigation and criminal defense firm re...y awarded $3.2 million to plaintiff earlier this y...nd ((Lexis Nexis) October 6, 2008 -- Attorneys in ...Murtha & Psoras] have successfully resolved a ... welder who was awarded more than $3 million by a ...
(Date:10/5/2008)...elp detect serious bacterial infections (SBIs) lik...ions in young infants who come to the emergency de.... Researchers at Children,s Hospital Boston, colla...niversity, show that a new diagnostic marker calle...risk for SBIs while potentially reducing unnecessa...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:New test could help catch serious infections in babies 2
...atest Journal of Advanced Nursing says expresses d...en education and practice in the nursing professio...on University says that despite sincere efforts by... change, the basic problems identified by Eve Bend...
...demy of Sciences (NAS) has chosen 15 scientists to...chievements. The awards will be presented on Apri...the Academy's 143rd annual meeting. The 2006 award... J. Carty Award FOR The Advancement Of Science, es...
...d on the sales pan masala and tobacco products nea...rala State Government in India. The products can b...tutions, according to the new rules. //A law is al...t this is strictly adhered to. The youth in the ...
...icer of Ontario has announced that it will be diff...tious disease outbreak. Many of Ontario's public h...on a full time basis,// and provincial laboratorie... equipment. The Province may be incapable of deali...
Other Medicine News:Health News:What nurses learn is not what they practice 2Health News:US Academy honors 15 for major contributions to science 2Health News:US Academy honors 15 for major contributions to science 3Health News:US Academy honors 15 for major contributions to science 4Health News:US Academy honors 15 for major contributions to science 5
(Date:10/6/2008)...ct - Company,s Bioabsorbable Stent - Also,Slated f...- Data from multiple clinical trials ...,s Genous Bio-engineered R,stent, will be presente...erapeutics symposium, TCT 2008, in Washington, D.C...c Medical Center in,Amsterdam will provide a Genou...
(Date:10/3/2008)...wire-FirstCall/ -- Amsterdam Molecular,Therapeutic...gene therapy,announced today that it intends to i...orization Application (MAA) for Glybera(R) for Lip...ilitating and potentially lethal,disease., The da...ies (22,patients in total) demonstrate that Glyber...
(Date:10/2/2008)...sults of Rosetta Genomics, microRNA-based,Test, mi...From non Squamous non Small Cell Lung Cancer,...the miRview(TM) Technology First Approved for Clin...plexity Molecular Pathology Lab ...pecting to Launch miRview(TM) Squamous Later This ...
(Date:10/2/2008)...wire/ -- Athera Biotechnologies AB and Dyax,Corp. ...ered into a,collaboration to discover and to devel...tment of cardiovascular inflammatory diseases., T... work by Athera,scientific founders, Professors Fr.... The research links naturally occurring antibodie...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4National Long Term Care Leaders to Release New Data Discuss Negative National Economic Jobs Impact 18955 1AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 1AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 2AutoImmune Inc Reports 2008 First Quarter Financial Results 18952 3Web Site Helps Patients Prepare for Hospital Stay 18948 1Web Site Helps Patients Prepare for Hospital Stay 18948 2Web Site Helps Patients Prepare for Hospital Stay 18948 3Development of new techniques to understand marble quality and durability 3248 1Development of new techniques to understand marble quality and durability 3248 2
...O, June 18, 2007 /PRNewswire-FirstCall/ -- Vical,I...ensee, AnGes MG,Inc. reported positive results fo... subjects to complete a Phase 3 trial of an,angiog...y,technology. Based on the findings that the prima...d with statistical,significance and that there wer...
...Italy, June 15 /CNW/ - Today AMADEO, one of the,fi...f two,angiotensin receptor blockers in hypertensi...ed at the European Society,of Hypertension, Milan...an reduces proteinuria to a significantly greater ...he results, Prof. Ellen Burgess, Foothills Hospita...
Other Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements.
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading.
The basic modular version of the VICTOR2 multilabel counter for fluorescence, luminescence and absorption measurements, with the stacker and the robotic loading configuration.
Medicine Products: